idiopathic%20pulmonary%20fibrosis
IDIOPATHIC PULMONARY FIBROSIS

Idiopathic pulmonary fibrosis is the progressive parenchymal scarring & loss of pulmonary function due to unidentifiable cause of lung injury.

It is a specific form of chronic fibrosing interstitial pneumonia with the histopathologic characteristics of usual interstitial pneumonia.

Approximately 5% of patients are asymptomatic. Common signs and symptoms are exertional dyspnea, nonproductive cough, finger clubbing and bilateral inspiratory crackles.

Supportive Therapy

  • Supportive measures in patients with acute exacerbation of idiopathic pulmonary fibrosis should include relief of dyspnea & provision of supplemental oxygen

Anti-Acid Therapy

  • Acid aspiration & gastroesophageal reflux/gastroesophageal reflux disease causing acute exacerbation of idiopathic pulmonary fibrosis may be treated with antacids (ie proton pump inhibitors, histamine-2 blocker receptor antagonists)
    • May help reduce the risk for microaspiration-associated lung injury 
  • Stress ulcer prophylaxis guidelines must be followed

Antibiotics

  • May be considered in idiopathic pulmonary fibrosis patients in acute exacerbation with radiographic findings of overlapping pneumonia
  • If the culture is negative, a 7-day course of antibiotic is recommended

Symptom Control for Cough & Dyspnea

  • Facial cooling with a fan & the use of opioids & anxiolytics may help alleviate refractory cough & dyspnea

Prevention of Venous Thromboembolism (VTE)

  • Venous thromboembolism is common in patients who were hospitalized due to acute exacerbation of idiopathic pulmonary fibrosis & routine measures should be employed

Vaccine

  • Influenza & pneumococcal vaccines should be offered to patients with idiopathic pulmonary fibrosis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.